Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management

Hormones

Volumn 8, Issue 1, 2009, Pages 23-28

  Raue, Friedhelm ^a   Frank Raue, Karin ^a  

^a Endocrine Practice   (Germany)

Author keywords

Medullary thyroid carcinoma; Multiple endocrine neoplasia type 2; Pheochromocytoma; Primary hyperparathyroidism; RET gene mutation

Indexed keywords

PROTEIN RET; RET PROTEIN, HUMAN;

AUTOSOMAL DOMINANT INHERITANCE; CANCER PREVENTION; DISEASE CLASSIFICATION; ENDOCRINE DISEASE; FAMILIAL DISEASE; GENE MUTATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROMA; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; PROTO ONCOGENE; REVIEW; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; GENETICS; GENOTYPE; MEDULLARY CARCINOMA; NEUROFIBROMATOSIS; PHENOTYPE; THYROID TUMOR; THYROIDECTOMY;

CARCINOMA, MEDULLARY; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 63049118581     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1218     Document Type: Review

References (21)

1. Raue F, Frank-Raue K, 2007 Multiple Endocrine Neoplasia Type 2: 2007 Update. Horm Res 68:101-104.
2. Kouvaraki MA, Shapiro SE, Perrier ND, et al, 2005 RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15: 531-544.
3. Berndt I, Reuter M, Saller B, et al, 1998 A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774. (Pubitemid 28496443)
4. Elisei R, Romei C, Cosci B, et al, 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92: 4725-4729. (Pubitemid 350223450)
5. Frank-Raue K, Rondot S, Schulze E, Raue F, 2007 Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53: 273-282. (Pubitemid 46971032)
6. Hubner RA, Houlston RS, 2006 Molecular advances in medullary thyroid cancer diagnosis. Clin Chim Acta 370: 2-8. (Pubitemid 44096946)
7. Mulligan LM, Kwok JBJ, Healey CS, et al, 1993 Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363: 458-469.
8. Donis-Keller H, Dou S, Chi D, et al, 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851-856. (Pubitemid 23216611)
9. Machens A, Niccoli-Sire P, Hoegel J, et al, 2003 for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525.
10. Eng C, Clayton D, Schuffenecker I, et al, 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579. (Pubitemid 26314449)
11. Yip L, Cote GL, Shapiro SE, et al, 2003 Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138: 409-416. (Pubitemid 36417678)
12. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H, 2005 Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90: 3999-4003. (Pubitemid 41058163)
13. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF, 2007 Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142: 800-805. (Pubitemid 350184105)
14. Schuffenecker I, Virally-Monod M, Brohet R, et al, and le Groupe d'Etude des Tumeurs a Calcitonine 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83: 487-491.
15. Frank-Raue K, Machens A, Scheuba, C, Niederle B, Dralle H, Raue F, and the German MEN 2 Study Group 2008 Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69: 259-263. (Pubitemid 352009032)
16. Brandi ML, Gagel RF, Angeli A, et al, 2001 Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 86: 5658-5671. (Pubitemid 33152604)
17. Frank-Raue K, Buhr H, Dralle H, et al, 2006 Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155: 229-236. (Pubitemid 44269439)
18. Colombo-Benkmann M, Li Z, Riemann B, et al, 2008 Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 158:811-816.
19. Robledo M, Gil L, Pollan M, et al, 2003 Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Research 63: 1814-1817.
20. Cebrian A, Lesueur F, Martin S, et al, 2005 Polymorphisms in the initiators of RET (rearranged during transfection. signalling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6268-6274.
21. Cardot-Bauters C, Leteurtre E, Leclerc L, et al, 2008 Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol 69: 506-510.